BellantiJA, BourkeAT, BuescherEL, et al.Report of dengue vaccine field trial in the Caribbean, 1963: a collaborative study. Bull World Health Organ, 1966; 35:93.
2.
BernardoL, HermidaL, MartinJ, et al.Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol, 2008; 153:849–854.
3.
BhattS, GethingPW, BradyOJ, et al.The global distribution and burden of dengue. Nature, 2013; 496:504–507.
4.
BlancG, and CminopetrosJ. Contributions to the study of vaccination against dengue. Bull Acad Med, 1929; 102:40–47.
5.
DejnirattisaiW, JumnainsongA, OnsirisakulN, et al.Cross-reacting antibodies enhance dengue virus infection in humans. Science, 2010; 328:745–748.
6.
DuangchindaT, DejnirattisaiW, VasanawathanaS, et al.Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A, 2010; 107:16922–16927.
7.
ForsheyBM, ReinerRC, OlkowskiS, et al.Incomplete protection against dengue virus type 2 re-infection in Peru. PLoS Negl Trop Dis, 2016; 10:e0004398.
8.
GoncalvezAP, EngleRE, St ClaireM, et al.Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A, 2007; 104:9422–9427.
9.
GuzmanMG, AlvarezM, and HalsteadSB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol, 2013; 158:1445–1459.
10.
HalsteadSB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine, 2013; 31:4501–4507.
11.
HalsteadSB, ChowJS, and MarchetteNJ. Immunological enhancement of dengue virus replication. Nat New Biol, 1973; 243:24–26.
12.
HalsteadSB, ScanlonJE, UmpaivitP, et al.Dengue and chikungunya virus infection in man in Thailand, 1962–1964. IV. Epidemiologic studies in the Bangkok metropolitan area. Am J Trop Med Hyg, 1969; 18:997–1021.
13.
HalsteadSB, SuayaJA, and ShepardDS. The burden of dengue infection. Lancet, 2007; 369:1410–1411.
14.
HalsteadSB, and ZompiS. Protective immune responses to dengue virus infection and vaccines: perspectives from the field to the bench. Front Immunol, 2015; 6:75.
15.
KliksSC, NimmanityaS, NisalakA, et al.Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg, 1988; 38:411–419.
16.
MongkolsapayaJ, DuangchindaT, DejnirattisaiW, et al.T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J Immunol, 2006; 176:3821–3829.
17.
OsorioJE, WallaceD, and StinchcombDT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Rev Vaccines, 2016; 15:497–508.
18.
RouvinskiA, Guardado-CalvoP, Barba-SpaethG, et al.Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature, 2015; 520:109–113.
19.
SabinAB. Research on dengue during World War II. Am J Trop Med Hyg, 1952; 1:30–50.
20.
SimmonsJS, St. John JH, and Reynolds FHK. Experimental studies of dengue. Philipp J Sci, 1932; 44:1–251.
21.
SridharS, LuedtkeA, LangevinE, et al.Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med, 2018; 379:327–340.
22.
ValdesI, GilL, LazoL, et al.Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates?. Arch Virol, 2016; 161:465–470.
23.
WeiskopfD, AngeloMA, de AzeredoEL, et al.Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A, 2013; 110:E2046–E2053.
24.
WeiskopfD, and SetteA. T-cell immunity to infection with dengue virus in humans. Front Immunol, 2014; 5:93.
25.
WhiteheadSS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine?. Expert Rev Vaccines, 2016; 15:509–517.
26.
Wilder-SmithA, HombachJ, FergusonN, et al.Deliberations of the strategic advisory group of experts on immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis, 2019; 19:e31–e38.
27.
WissemanCL, SweetBH, and RosenzweigEC. Attenuated living type 1 dengue vaccines. Am J Trop Med Hyg, 1963; 12:620–623.
28.
YauchLE, PrestwoodTR, MayMM, et al.CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol, 2010; 185:5405–5416.
29.
YauchLE, ZellwegerRM, KotturiMF, et al.A protective role for dengue virus-specific CD8+ T cells. J Immunol, 2009; 182:4865–4873.
30.
ZellwegerRM, EddyWE, TangWW, et al.CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol, 2014; 193:4117–4124.
31.
ZellwegerRM, MillerR, EddyWE, et al.Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog, 2013; 9:e1003723.
32.
ZellwegerRM, PrestwoodTR, and ShrestaS. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe, 2010; 7:128–139.
33.
ZellwegerRM, TangWW, EddyWE, et al.CD8+ T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J Virol, 2015; 89:6494–6505.
